Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial.
Xu M, Sun K, Xu W, Wang C, Yan D, Li S, Cong L, Pi Y, Song W, Sun Q, Xiao R, Peng W, Wang J, Peng H, Zhang Y, Duan P, Zhang M, Liu J, Huang Q, Li X, Bao Y, Zeng T, Wang K, Qin L, Wu C, Deng C, Huang C, Yan S, Zhang W, Li M, Sun L, Wang Y, Li H, Wang G, Pang S, Zheng X, Wang H, Wang F, Su X, Ma Y, Zhang W, Li Z, Xie Z, Xu N, Ni L, Zhang L, Deng X, Pan T, Dong Q, Wu X, Shen X, Zhang X, Zou Q, Jiang C, Xi J, Ma J, Sun J, Yan L. Xu M, et al. Among authors: pan t. BMC Med. 2023 Oct 9;21(1):388. doi: 10.1186/s12916-023-03089-x. BMC Med. 2023. PMID: 37814306 Free PMC article. Clinical Trial.
Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS).
Chen X, Jiang H, Li H, Kuang H, Chen L, Ma J, Zhang Q, Pan T, Yang W; SUCCESS study investigators. Chen X, et al. Among authors: pan t. Diabetes Obes Metab. 2023 Jan;25(1):272-281. doi: 10.1111/dom.14873. Epub 2022 Oct 14. Diabetes Obes Metab. 2023. PMID: 36099069 Clinical Trial.
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
Gu J, Zhang H, Xue Q, Wang L, Cheng Z, Zhang Y, Li Q, Yuan L, Li Y, Dong J, Huo Y, Tang X, Hu L, Wang X, Hua F, Shen L, Cheng J, Zhou H, Xu Y, Yang T, Wang C, Xu J, Shen J, Zhang Y, Zhang X, Hong D, Guan X, Xiao X, Wang G, Liu Y, Fu L, Chen J, Cheng X, Ding Y, Liu L, Yao Q, Zhang X, Li L, Zhang P, Deng C, Jiang C, You L, Wang K, Zhang S, Xiao J, Liu W, Du X, Shang X, Pan T, Lei C, Guo S, Zhang Z. Gu J, et al. Among authors: pan t. J Orthop Translat. 2022 Oct 29;38:117-125. doi: 10.1016/j.jot.2022.06.007. eCollection 2023 Jan. J Orthop Translat. 2022. PMID: 36381249 Free PMC article.
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Wang Y, Jiang C, Dong X, Chen M, Gu Q, Zhang L, Fu Y, Pan T, Bi Y, Song W, Xu J, Lu W, Sun X, Ye Z, Zhang D, Peng L, Lin X, Dai W, Wang Q, Yang W. Wang Y, et al. Among authors: pan t. Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15596. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38618970
3,183 results